News - Merck & Co, Endocyte


Current filters:

Merck & CoEndocyte

Popular Filters

Merck and Endocyte pull CMA for vintafolide and companion imaging component in EU


US pharma giant Merck & Co and Endocyte have withdrawn their conditional marketing authorization applications…

EndocyteEuropeMerck & CoOncologyPharmaceuticalRegulationResearchvintafolide

Endocyte plummets on decision to stop vintafolide Ph III trial; posts financials


US pharma giant Merck & Co and partner Endocyte revealed on Friday that the Data Safety Monitoring Board…

EndocyteFinancialMerck & CoOncologyPharmaceuticalResearchvintafolide

EMA/CHMP backs approval of Merck ovarian cancer drug Vynfinit and companion diagnostics


The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

EndocyteEuropeFolcepriMerck & CoNeocepriOncologyPharmaceuticalRegulationVynfinit

New data on Merck and Endocyte’s vintafolide in ovarian cancer

New data on Merck and Endocyte’s vintafolide in ovarian cancer


Merck & Co and partner Endocyte today announced the on-line publication of results from the randomized…

EndocyteMerck & CoOncologyPharmaceuticalResearchvintafolide

Merck & Co in potential $1 billion deal for cancer drug candidate vintafolide


US drug giant Merck & Co (NYSE: MRK) has entered into an agreement to develop and commercialize Endocyte's…

BiotechnologyEndocyteetarfolatideLicensingMerck & CoOncologyPharmaceuticalvintafolide

Back to top